Across TCGA pan-cancer cohorts, CYSRT1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CYSRT1 data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CYSRT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYSRT1 expression acts as an unfavorable survival marker.

LIHC and CESC are the cancer types where CYSRT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
CESC	DFS	Median	II,III,IV	0.227	0.710	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CYSRT1 tumor-vs-normal RNA expression · all CYSRT1 data types